AD Therapeutics Studies

Filters
Enrollment Status
Study Type
Age Range
Cognitive Status
, ,
Approximately fifty percent of people diagnosed with Alzheimer’s disease or other types of dementia will receive hospice care at the end of their life. Of these, over seventy percent will be prescribed psychiatric medications for management of agitation. Recent research suggests that derivatives of cannabis can be beneficial in controlling agitation and distress without the side effects of medications commonly used to treat agitation. This project aims to test the efficacy of an oral combination of two cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), for the treatment of agitation in participants with a diagnosis of dementia who are eligible for hospice and experiencing agitation. The study will recruit 150 participants from 15 clinical trial sites in the United States over a 2-year period. To facilitate recruitment and retention and to monitor long-term safety of the THC/CBD combination, completers of the double-blind study will then have the option to participate in a 6-month, open-label extension study.
, ,
This study will investigate whether CT1812, a novel and promising therapeutic candidate can halt or slow the process of Alzheimer’s disease. In 2022, a nationwide randomized controlled clinical trial will enroll approximately 540 individuals from Alzheimer’s Clinical Trial Consortium (ACTC) sites and sites from other partnering institutions. Participants aged 50 to 85 with mild cognitive impairment (MCI) due to Alzheimer’s disease, or mild Alzheimer’s disease who have elevated amyloid in the brain (as measured by PET or CSF), will be sought. Participants will be randomized to receive CT1812 or placebo for 18 months. In addition to a battery of cognitive measures, the study will use a variety of biomarkers to evaluate target engagement and assess changes in neurodegeneration and disease progression. This study will leverage the centralized resources, shared expertise, and experienced trial sites of the ACTC to investigate the potential of CT1812 to preserve cognitive function for individuals with early Alzheimer’s disease.
, , ,
The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF) and was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process. The newest iteration of the study, called ADNI4, will begin at the end of 2022 and aims to recruit 750 new participants age 55-90 and bring over 750 rollover participants from ADNI3.